

NON-EXECUTIVE DIRECTOR RETIREMENT

Perth, Australia; 12 November 2025 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other neurological conditions, today announces the retirement of Mr Terry Budge at the conclusion of today’s AGM on 12 November 2025.

Mr Budge has served on the Board since January 2021 as one of the early directors of the Company and was instrumental in supporting the Company’s initial public offering in June 2021. Terry has made a significant contribution to the Company during his tenure to support the translation of ARG-007 originating from the University of Western Australia and the Perron Institute into a development asset. In addition, he has overseen the financial stewardship of the Company as Chair of the Audit & Risk Committee and played a key role in capital raising activities over the past five years to support the clinical development of ARG-007.

The Board and Management team thanks Mr Budge for his dedication and support of Argenica during his tenure and wishes him well.

Authorised for release by the Chair and Company Secretary.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has recently completed a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.

.